title: Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
authors.affiliation: Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Université Paris 7, 75010, Paris, France. prof.faivre@gmail.com.|Medical Oncology, Hôpital Beaujon, 100 Avenue du Général Leclerc, 92110, Clichy, France. prof.faivre@gmail.com.
authors.forename: Sandrine
authors.initials: S
authors.lastname: Faivre
authors.affiliation: Center of Experimental Therapeutics, Centre Hospitalier Universitaire Lausanne (CHUV), rue du Bugnon 21, 1011, Lausanne, Switzerland.
authors.forename: Armand
authors.initials: A
authors.lastname: de Gramont
authors.affiliation: Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Université Paris 7, 75010, Paris, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Raymond
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib